Formulary Search Results for: CALCIUM AND VITAMIN D
9.6.4 Vitamin D - View Category
Prescribing Notes:
Domnisol® is a monthly preparation and could be prescribed for patients where monthly administration would be advantageous. Domnisol® currently is associated with an acquisition cost advantage compared to daily colecalciferol (September 2024).
4.1.1.2 Hypnotics for chronic insomnia - View Category
Restrictions:
Restricted to use in patients where sleep hygiene advice has been unsuccessful and the use of cognitive behavioural therapy for insomnia (CBT-I) has failed or for whom CBT-I is unsuitable or unavailable.
Prescribing Notes:
- For the treatment of adult patients with chronic insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.
- Sleepio® is a six-week programme based on CBT-I. Sleepio® is used to treat insomnia and is available free on the NHS. For more information visit Sleep | NHS inform
6.1.1.2 Intermediate- and long-acting insulins - View Category
Restrictions:
Restricted to initiation by clinicians, either in primary care or the acute setting, experienced in the treatment of diabetes. Restricted to use in accordance with local guidance which includes information on preferred alternative options.
Prescribing Notes:
Note: Insulin degludec is available in two strengths and caution should be taken in prescribing, dispensing and administration to ensure the correct strength is received.
13.2.6 Bath and Shower Emollients - View Category
Restrictions:
Restricted to use only when skin is infected or if infection is a frequent complication (e.g. folliculitis or secondary infection of eczema).
Prescribing Notes:
Not for prolonged use unless clinically indicated.
1.3.5 Proton pump inhibitors - View Category
Restrictions:
Use is restricted to patients in the immediate period (2 weeks) after bariatric surgery.
Prescribing Notes:
- The dispersible preparations are considerably more expensive than omeprazole capsules and should not be used unless necessary.
- Omeprazole MUPS are not licensed for enteral feeding tube administration and appear to be associated with an increased risk of tube blockages. In contrast, lansoprazole orodispersible tablets are licensed and are the preferred formulation in NHSGGC for this route of administration.
13.2.8 Urea-containing emollients - View Category
8.1.2 Anthracyclines and other cytotoxic antibiotics - View Category
5.3.1.4 Other retrovirals - View Category
Restrictions:
The use in combination with other antiretroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected adults and adolescents above 12 years of age is restricted to use by HIV specialists.
3.2.2 Combination inhaled devices - View Category
Restrictions:
Restricted for use in asthma patients according to the BTS/SIGN asthma guidelines.
Prescribing Notes:
Preferred brands and devices:
- DuoResp® Spiromax (dry powder inhaler)
- Fobumix® Easyhaler (dry powder inhaler
- Symbicort® Turbohaler (dry powder inhaler)
To prevent confusion, prescribe inhaler devices by brand name.
Non-Formulary indication:
Treatment of patients with chronic obstructive pulmonary disease (COPD) with forced expiratory volume in 1 second (FEV1) 50% to 70% predicted normal (post bronchodilator) and an exacerbation history despite regular bronchodilator therapy.
6.5.2 Posterior pituitary hormones and antagonists - View Category
Restrictions:
Desmopressin tablets are restricted to use in patients unable to use intramuscular preparations. Intravenous desmopressin is restricted to use in specialist haemophilia centres.
Prescribing Notes:
- Used for treatment of diabetes insipidus, primary nocturnal enuresis and postoperative polyuria or polydipsia. Due to the high level of adverse reactions, desmopressin nasal spray is no longer indicated for primary nocturnal enuresis. Oral formulations should be considered as an alternative.
- For use in the symtomatic treatment of nocturia due to idiopathic nocturnal polyuria see section 7.4.2